Vaccination of biliary tract cancer patients with four peptides derived from cancer-testis antigens.
In the context of a Phase I clinical trial, the long-term vaccination of advanced biliary tract cancer patients with peptides derived from four distinct cancer-testis antigens resulted in remarkable disease stability and in the elicitation of antigen-specific T-cell responses.
Institute of Advanced Biomedical Engineering and Science; Tokyo Women's Medical University; Tokyo, Japan.
Atsushi
A
Aruga
biliary tract cancer; cancer vaccine; cancer-testis antigen; immunotherapy; peptide vaccine